Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.
The gallbladder signal is real and it is mostly the weight loss, not the drug. Rapid loss increases biliary cholesterol saturation and reduces gallbladder motility, which is the classic recipe for stones — the same effect appears after bariatric surgery and in very-low-calorie dieting, without any GLP-1 involved. Trial data shows a modest absolute increase in cholelithiasis, concentrated in faster losers.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
So the question, as narrowly as I can put it: how much of the gallbladder signal is the drug and how much is simply the rate of weight loss, because the answer changes what you can do about it. Practical detail welcome, however dull — the duller the better.
PharmacoVig_BOS said:The gallbladder signal is real and it is mostly the weight loss, not the drug.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
PharmacoVig_BOS said:The gallbladder signal is real and it is mostly the weight loss, not the drug.
I read this differently from PharmacoVig_BOS, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAnswering the narrow version, because the broad one does not have a single answer. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.
SarahChen_PharmD said:Agreed, and subgroup analyses deserve particular suspicion.
Mine went the same way, slower. Posting only so the count is not one.